Feburic 20mg Tablet
Salt Composition: Febuxostat
Expiry Date: 01/2028
Buy at $10.15
Inclusive of all taxes
15 tablets in 1 strip
About The Product
Used to lower uric acid levels in conditions like gout.
Description
- Feburic 20mg Tablet is a tablet prescribed by the doctor that is mainly used to reduce high uric acid levels (hyperuricemia) to prevent gout attacks, joint damage, and related inflammation from crystal buildup.
- Feburic 20mg Tablet contains Febuxostat that non-competitively inhibit at the enzyme's active site, which lowers uric acid synthesis.
Uses
- Reduce Hyperuricemia
Side Effects
Like any other chemical based medication, Feburic 20mg Tablet also has certain common side effects. Consult your doctor, if side effects persist for longer period of time.
- Pain in your muscles, bones, and joints Headache
- Headache
- Cough
- Diarrhea
- Nausea
- Weakness
- Itchy skin or rash
- Fever
- Pain in your muscles, bones, and joints
- Constipation
- Low Potassium
- Stomach Pain
- Severe Skin Reactions
- Pneumonitis
- Severe Allergic reaction
- Bone Marrow Supression
- Acute Kidney Injury
- Liver Infection
How To Use
- The standard recommended starting dosage of Feburic 20mg Tablet is once daily. This medicine is taken orally as whole with or without food but not on an empty stomach, without breaking, biting or chewing.
- Consult your doctor for exact dosage that is especially meant for you.
How It Works
- Feburic 20mg Tablet contains Febuxostat, a xanthine oxidase inhibitor. The enzyme xanthine oxidase, which breaks down purines by converting hypoxanthine to xanthine and subsequently to uric acid, is specifically blocked by febuxostat.
- Urate crystals in joints are dissolved and gout flare-ups are avoided because to this non-competitive inhibition at the enzyme's active site, which lowers uric acid synthesis.
Safety Advice
FAQs
Feburic 20mg Tablet should be swallowed whole with water, generally at consistent time each day.
Avoid breaking, biting and chewing of tablet to maintain its efficacy.
References
- Takata, T., Taniguchi, S., Mae, Y., Kageyama, K., Fujino, Y., Iyama, T., ... & Isomoto, H. (2025). Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Scientific Reports, 15(1), 8990. https://pubmed.ncbi.nlm.nih.gov/40089552/
- Lin, M., Zhang, H., Wu, H., Zhao, D., Nan, Z., & Fu, Y. (2025). Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 12, 1657274. https://pmc.ncbi.nlm.nih.gov/articles/PMC12597919/
- Sarvepalli, R., & Penabaka, V. (2025). A Review on Febuxostat as Uric Acid Lowering Agent. Asian Journal of Medical and Pharmaceutical Sciences, 13(1), 17-20.
- Fan, X., & Wang, R. (2025). Drug-related gastric perforation secondary to prolonged febuxostat administration: a case report. Clinical Therapeutics.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
